Highlights Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Market Closed - OTC Markets Other stock markets 20:48:55 10/05/2024 BST			5-day change	1st Jan Change
0.01 ^USD	-7.49%		0.00%	-54.55%

02-22	Baudax Bio, Inc. Filed for Bankruptcy	CI
2023	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Baudax Bio, Inc. to Initiate TI-168 Clinical Development	18/10/23	CI
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	29/09/23	CI
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/08/23	CI
Baudax Bio Shares More Than Double After Purchase of Cell Therapy Developer TeraImmune	30/06/23	MT
Baudax Bio Acquires TeraImmune	30/06/23	MT
Baudax Bio, Inc. acquired TeraImmune, Inc. for $9.7 million.	29/06/23	CI
Baudax Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Baudax Bio, Inc. Announces Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 for NMB in Patients Undergoing Elective Surgery	25/04/23	CI
Baudax Bio, Inc. Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000	27/03/23	CI
Earnings Flash (BXRX) BAUDAX BIO Reports Q4 Revenue $310,000	23/02/23	MT
Baudax Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23/02/23	CI
Baudax Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Baudax Bio, Inc. Announces Positive Outcome of Interim Analysis of Phase Ii Randomized Trial for B1000	24/01/23	CI
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery	08/12/22	CI
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
Baudax Bio Receives Notice of Patent Allowance Covering Anjeso for Treatment of Moderate to Severe Pain	22/08/22	MT
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Earnings Flash (BXRX) BAUDAX BIO Posts Q2 Revenue $300,000	11/08/22	MT
Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000	01/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Highlights

Filters